Session Chair Profile
U.S. Public Channels, Healthcare and Life Sciences Solutions Executive, IBM
Mr. Crites is responsible for using transformational forces of AI, near infinite compute and storage to develop and execute revenue generating opportunities in the Healthcare, Life Sciences & Govt. (US) Verticals. His primary responsibility is leading IBM Systems in support of Watson Health, what the company identifies as its current ‘moonshot’ working to advance health at global scale. Mr. Crites has a passion for the ethical use of data and technology to advance Precision Medicine. He advocates and is pushing the industry to move from siloed samples sizes in the 10s or 100s to deep and diverse data sets in the millions and apply advanced artificial intelligence to accelerate the time from bench to clinic dramatically. To this end, Mr. Crites advises major healthcare and life sciences organizations and is active in large data sharing programs. Mr. Crites is also passionate about utilizing ethical data use as a core competency and competitive advantage vs. a cost of doing business in the “land grab” approach to data acquisition and analytics.
Mr. Crites joined IBM in 2001 as an Enterprise Sales Specialist. He has continually advanced throughout his career holding various domestic and international sales, consulting and leadership roles. He has been part of or developed first of the kind initiatives that led to new products, services, revenue, and growth. He is a transformational executive who quickly evolves too rapidly changing competitive environments and utilizes these talents to help clients succeed beyond their expectations and has advised many of the Fortune 500 companies in the use of advanced technologies to transform their businesses. Click here for full bio.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: This session will focus on different views and approaches to advance precision medicine data collection and use in the post-Facebook-Cambridge Analytica era. We will hear from various areas of our industry on new technological, medical and legal approaches to data acquisition and use that will move us closer to achieving the full promise of big data and AI to democratize precision medicine.